This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
CCP110 / Centriolar coiled-coil protein of 110 kDa · IHC design guide
Design Immunohistochemistry for CCP110
Plan chromogenic paraffin-section IHC around granular cytoplasmic staining, with high signal in bronchial ciliated cells and late spermatids (HPA tissue IHC). Start with 2–5 μg/ml of the IHC-validated antibody (datasheet A05058-1), and interpret staining cautiously because agreement with RNA expression is low (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
CCP110 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Granular cytoplasm in tissue sections (HPA tissue IHC) | |
| Staining pattern | Granular cytoplasm; high in ciliated cells and late spermatids (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A05058-1) | |
| Positive control | Bronchus+4 more · see all | |
| Negative control | Adipose tissue+1 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Tissue staining has low agreement with RNA expression (HPA tissue IHC) | |
| Regulation | Ubiquitination promotes degradation (UniProt) | |
| Isoform / epitope | 2 isoforms; epitope coverage is unknown (UniProt) |
Section 1
Recommended CCP110 IHC & IF Protocols
The catalog antibody uses EDTA pH 8.0 retrieval (datasheet A05058-1). One published CCP110 tissue-section protocol provides a citrate-based alternative (PMC9996364).
| Sample | Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet A05058-1) |
| Fixation | Image fixative and duration unreported (datasheet A05058-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A05058-1); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A05058-1) |
| Primary antibody | Rabbit anti-CCP110, 2-5μg/ml (datasheet A05058-1) |
| Primary incubation | Overnight at 4 °C (datasheet A05058-1) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A05058-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | CCP110-positive staining in ciliated cells (cell body) of bronchus (HPA tissue IHC: High). HPA tissue profile: Granular cytoplasmic expression in most tissues, including testis. No signal in the no-primary control. |
💡Decision noteStart with EDTA pH 8.0 for the catalog antibody (datasheet A05058-1); try citrate pH 6.0 if optimizing retrieval (PMC9996364).
Section 2
What Is the Expected CCP110 Staining Pattern?
CCP110 localizes to centrioles, centrosomes and cilium basal bodies and has no transmembrane segment (UniProt O43303 localization and topology). In paraffin-section IHC, expect granular cytoplasmic staining, especially in bronchial ciliated-cell bodies and testicular late spermatids (HPA tissue IHC). HPA rates the tissue staining Approved but reports low consistency between antibody staining and RNA expression; interpret intensity with that limitation (HPA tissue IHC).
| Granular cytoplasmic stain is strong in bronchial ciliated-cell bodies or elongated or late spermatids (HPA tissue IHC). | This matches HPA's High observations in those cell populations (HPA tissue IHC). Small cytoplasmic granules fit CCP110's centrosomal and centriolar localization, although chromogenic IHC alone cannot identify an individual centriole (UniProt O43303 localization; general IHC practice). |
| A sharp nuclear, surface-membrane or extracellular pattern dominates instead of cytoplasmic granules (HPA tissue IHC; UniProt O43303 topology). | Treat the compartment mismatch as possible artefact: UniProt places CCP110 at centrosomal structures and reports no transmembrane segment (UniProt O43303 localization and topology). Compare the pattern with a known-positive section and the negative reagent control before scoring it (general IHC practice). |
| Adipocytes or smooth muscle cells stain strongly while expected positive cells do not (HPA tissue IHC). | HPA reports CCP110 as Not detected in adipocytes and smooth muscle cells (HPA tissue IHC). A signal confined to those cells warrants investigation of cross-reactivity or endogenous detection activity; morphology alone cannot distinguish the two (general IHC practice). |
| Brown precipitate is widespread across tissue compartments, obscuring cell borders and the expected granular pattern (HPA tissue IHC). | Diffuse background cannot be scored as CCP110-positive cells (general IHC practice). Review blocking, wash stringency, antibody concentration and chromogen development, then compare with a section processed without primary antibody (general IHC practice). |
| No convincing signal appears in bronchial ciliated-cell bodies or testicular late spermatids (HPA tissue IHC). | These are HPA High reference populations, so a blank result leaves assay performance unresolved (HPA tissue IHC). Check section identity and positive-control performance before interpreting another tissue as negative; HPA's RNA–staining consistency is low (HPA tissue IHC; general IHC practice). |
💡Expected CCP110 appearanceCall a positive IHC result when granular cytoplasmic staining is convincing in bronchial ciliated-cell bodies or elongated or late spermatids, where HPA reports High staining (HPA tissue IHC); dominant nuclear or surface-membrane staining is a compartment mismatch (UniProt O43303 localization and topology).
| Cell population and tissue | HPA records High staining in bronchial ciliated-cell bodies and late spermatids, Medium in several other listed cell populations, and Not detected in adipocytes and smooth muscle cells (HPA tissue IHC). Score the identified cell population rather than assigning one intensity to an entire section (general IHC practice). |
| Subcellular resolution | UniProt places CCP110 at centrioles, centrosomes and basal bodies (UniProt O43303 localization). HPA describes tissue IHC as granular cytoplasmic (HPA tissue IHC). A chromogenic granule can support this pattern, but cannot establish its precise organelle without higher-resolution localization (general IHC practice). |
| Ciliation state | CCP110 is removed from the mother centriole during initiation of ciliogenesis and remains at the daughter centriole in ciliated cells (UniProt O43303 localization). Do not require identical centriole-level placement across every cell; assess the tissue IHC pattern at the resolution available (general IHC practice). |
| Antibody evidence and isoforms | HPA lists antibody HPA039402 as IHC Approved and reports low consistency between antibody staining and RNA expression (HPA tissue IHC; HPA antibody record). UniProt lists two isoforms, but the supplied evidence does not establish whether this antibody detects them equally (UniProt O43303 isoforms). |
| IF/ICC: what localization is reported? | HPA reports an approved centriolar-satellite localization in ICC-IF (HPA subcellular). That observation can guide localization checks, while this section's primary readout remains granular cytoplasmic staining in paraffin-section IHC (HPA tissue IHC). |
| Situation | Likely cause | Next action |
|---|---|---|
| The positive-control section has no stain. | The assay may have failed, or the expected cell population may be absent from the section (general IHC practice). | Confirm bronchial ciliated-cell bodies or testicular late spermatids are present, then check antibody dilution, retrieval, detection reagents and run controls (HPA tissue IHC; general IHC practice). |
| Granules are too faint to score. | Weak detection or a cell population with lower observed staining may explain the result (general IHC practice; HPA tissue IHC). | Compare with HPA High reference cells before adjusting antibody dilution or detection conditions; HPA reports Medium staining in several other listed populations (HPA tissue IHC; general IHC practice). |
| Nuclei or cell surfaces dominate the stain. | The pattern conflicts with CCP110's centrosomal localization and lack of a transmembrane segment (UniProt O43303 localization and topology). | Review morphology, compare a known-positive section and inspect the no-primary control before assigning CCP110 positivity (general IHC practice). |
| The whole section has diffuse brown background. | Nonspecific antibody binding, incomplete washing or excessive chromogen development can obscure a granular signal (general IHC practice). | Review blocking and washes, titrate the primary antibody or shorten chromogen development; judge improvement against the no-primary control (general IHC practice). |
| Adipocytes or smooth muscle cells appear strongly positive. | Both are reported Not detected by HPA; cross-reactivity or endogenous detection activity is possible (HPA tissue IHC; general IHC practice). | Compare no-primary and appropriate detection controls, then reassess whether the expected positive cell population shows granular cytoplasmic staining (general IHC practice; HPA tissue IHC). |
| A tissue looks negative despite otherwise working controls. | Cell composition and staining level vary across HPA's listed tissues; antibody staining also has low consistency with RNA expression (HPA tissue IHC). | Score the relevant cells separately, document the control result and report the finding as an IHC observation without inferring absent CCP110 protein from a single negative section (general IHC practice; HPA tissue IHC). |
Experiment evidence
IHC & IF images showing CCP110 staining
A05058-1 · IHCIHC analysis of CP110 using anti-CP110 antibody (A05058-1). CP110 was detected in a paraffin-embedded section of human breast cancer tissue.
A05058-1 · IHCIHC analysis of CP110 using anti-CP110 antibody (A05058-1). CP110 was detected in a paraffin-embedded section of human colorectal adenocarci
A05058-1 · IFIF analysis of CP110 using anti-CP110 antibody (A05058-1). CP110 was detected in an immunocytochemical section of HELA cells. Enzyme antigen
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000103540-CCP110/tissue/cerebral+cortex#imid_10232197
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000103540-CCP110/tissue/colon#imid_10232123
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000103540-CCP110/tissue/liver#imid_10232132
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000103540-CCP110/tissue/kidney#imid_10232125
HPA · ICC-IF REHHuman Protein Atlas immunofluorescence, REH, antibody HPA039402; green = CCP110, blue = nucleus, red = microtubules.
HPA · ICC-IF REHHuman Protein Atlas immunofluorescence, REH, antibody HPA039402; green = CCP110, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for CCP110 IHC & IF
🧪Run bronchus first: ciliated cell bodies should stain (HPA: High in bronchus ciliated cells). Use adipose tissue as the negative tissue; adipocytes should remain at background (HPA: Not detected in adipocytes). On the bronchus slide, use adjacent cells without specific staining as an internal background reference, without assuming every nonciliated cell is negative.
Positive control tissue: Bronchus (Ciliated cells (cell body), HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show CCP110 in REH, U-251MG, Sperm, with annotated localisation: Centriolar satellite (approved) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control and a concentration-matched rabbit IgG isotype control appropriate to the catalog antibody’s clonality (caption: rabbit anti-CP110; standard IHC practice). Confirm specificity with a validated CCP110 knockout specimen or peptide competition if the immunizing peptide is available, and block endogenous peroxidase before HRP/DAB detection in bronchus (standard IHC practice; caption: HRP/DAB).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected A05058-1 paraffin-section caption does not state a fixative (caption: fixative not stated). The demonstrated IHC preparation used heat retrieval in EDTA at pH 8.0, but retrieval dependence has not been established by a comparison in the supplied evidence (caption: EDTA retrieval). IF/ICC may help resolve the reported centriolar localization; comparative ease of frozen sections is unreported, and bronchial cilia should be distinguished from cell-body staining during scoring (HPA: centriolar satellite localization; HPA: High in bronchus ciliated cell bodies).
HPA tissue IHC evidence for CCP110
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Low consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Bronchus | Ciliated cells (cell body) | High | Protein (IHC) | HPA → |
| Testis | Elongated or late spermatids | High | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Medium | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Medium | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Medium | Protein (IHC) | HPA → |
Section 3
Advanced CCP110 IHC Tips
Troubleshoot CCP110 staining in paraffin sections by checking retrieval, controls, compartment, and cell type before comparing staining intensity across samples.
Which retrieval conditions should I start with for CCP110 IHC?
Start with heat-mediated antigen retrieval in EDTA at pH 8.0, the condition used for the catalog antibody in paraffin-embedded human breast cancer tissue (datasheet A05058-1). Keep heating and cooling conditions consistent across sections, and compare retrieved tissue with a section processed without retrieval to assess whether staining depends on that step (standard IHC practice). The caption reports 2 μg/ml primary antibody overnight at 4°C, so retain those conditions while evaluating retrieval (datasheet A05058-1). If staining remains weak, test another retrieval condition on adjacent sections and judge it against tissue morphology, background, and the expected cellular pattern (standard IHC practice; UniProt O43303 localisation).
How should I troubleshoot weak CCP110 staining when fixation history is uncertain?
The catalog image documents a paraffin-embedded section but does not state its fixative, so target-specific fixation sensitivity is unknown (datasheet A05058-1). Record the available fixation and processing history for each specimen, then compare sections processed alike before attributing an intensity difference to CCP110 biology (standard IHC practice). Use EDTA retrieval at pH 8.0 and the documented 2 μg/ml overnight primary incubation as a reproducible starting point (datasheet A05058-1). If morphology is damaged or staining is uneven, examine section quality and processing alongside retrieval; neither the tissue staining profile nor CCP110's topology establishes a target-specific fixation effect (standard IHC practice; HPA tissue IHC; UniProt O43303 topology).
What cellular pattern should count as plausible CCP110 staining?
Interpret a discrete centrosomal or pericentrosomal signal in light of CCP110's reported centriole, centrosome, and basal-body localisation (UniProt O43303 localisation). Centriolar-satellite localisation is also reported in cell imaging, while tissue IHC shows granular cytoplasmic expression in most tissues (HPA subcellular; HPA tissue IHC). Inspect high magnification fields with a counterstain to distinguish puncta from diffuse cytoplasmic chromogen and to assign signal to individual cells (standard IHC practice). Because CCP110 can be removed from the mother centriole during ciliogenesis, a missing punctum in one cell should be interpreted with cell state and staining controls in mind (UniProt O43303 localisation; standard IHC practice).
Could isoforms or epitope accessibility explain discordant CCP110 staining?
CCP110 has 2 annotated isoforms, but the supplied catalog caption does not map the antibody epitope or establish isoform-specific detection (UniProt O43303 isoforms; datasheet A05058-1). Check an available epitope sequence against both isoforms before treating different staining patterns as evidence of alternative splicing (standard IHC practice; UniProt O43303 isoforms). CCP110 has no annotated transmembrane segment and has several recorded phosphorylation sites, including residues 170 and 194; those facts alone do not establish epitope masking in sections (UniProt O43303 topology and modified residues). Compare serial sections under matched retrieval and detection conditions, and seek independent evidence before assigning a signal to an isoform or modification state (standard IHC practice).
How can IF help assess the CCP110 pattern seen by IHC?
On the separate IF/ICC workflow, multiplex CCP110 with a marker identifying the expected cell type so a punctum can be assigned to the appropriate cell (standard IF practice; HPA tissue IHC). Select spectrally separated fluorophores after checking tissue autofluorescence in an unstained control, and keep acquisition settings consistent between samples (standard IF practice). Because CCP110 is reported at intracellular centrioles and centrosomes and has no transmembrane segment, use permeabilisation appropriate for access to that intracellular epitope (UniProt O43303 localisation and topology; standard IF practice). Compare the resulting pattern with the reported centriolar-satellite localisation, while recognising that IF localisation alone does not validate chromogenic tissue staining (HPA subcellular; standard IHC/IF practice).
How do I distinguish CCP110 signal from chromogenic background?
The catalog tissue image used 10% goat serum blocking, a peroxidase-conjugated secondary, and DAB development; these are documented conditions for that image (datasheet A05058-1). Include a section without primary antibody and use a peroxidase-blocking step to assess secondary-associated staining and endogenous enzyme activity (standard IHC practice). Compare background in tissue edges, damaged areas, and uniformly stained regions with the discrete or granular patterns expected from localisation and tissue IHC evidence (standard IHC practice; UniProt O43303 localisation; HPA tissue IHC). If background obscures cells, adjust blocking, antibody concentration, washing, or DAB development one variable at a time while retaining a comparable positive control (standard IHC practice).
How should I quantify CCP110 staining across tissue sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and compartment before scoring, since tissue IHC describes granular cytoplasmic staining while CCP110 is also associated with centrioles (HPA tissue IHC; UniProt O43303 localisation). For broader chromogenic staining, report the percentage of positive cells and an H-score using the same intensity bins across samples; for resolvable puncta, report puncta-positive cells or puncta density per mm² (standard IHC practice). Normalise each measure to the number of eligible cells or the measured viable tissue area, and score matched regions under the same threshold and imaging conditions (standard IHC practice). Document cell-type composition because reported staining differs among tissue cell populations, and avoid interpreting a changed score without examining that composition (HPA tissue IHC; standard IHC practice).
When is an apparent CCP110-positive cell likely to be an artefact?
Give greatest weight to staining assigned to an intact cell in a plausible cytoplasmic or centriolar distribution, rather than chromogen deposited outside cells (HPA tissue IHC; UniProt O43303 localisation; standard IHC practice). Check the cell identity against the reported tissue pattern: bronchial ciliated cells and testicular elongated or late spermatids have high staining, whereas adipocytes and smooth muscle cells are reported as not detected (HPA tissue IHC). Treat edge staining, necrotic areas, and signal persisting without primary antibody as possible preparation or detection artefacts, and check endogenous peroxidase controls (standard IHC practice). HPA labels its tissue IHC evidence Approved while reporting low consistency with RNA expression, so resolve unexpected findings with morphology and independent controls before claiming biological specificity (HPA tissue IHC).
Boster reagents
Best CCP110 / Centriolar coiled-coil protein of 110 kDa IHC Antibodies
Anti-CCP110 antibody A05058-1 has human paraffin-section IHC and HELA-cell IF images (catalog image captions); listed reactivity covers human, mouse and rat (catalog reactivity).
Real IHC data
Anti-CP110/CCP110 Antibody ®
Cat # A05058-1
A05058-1 is listed for IHC, with images of paraffin-embedded human breast cancer, colorectal adenocarcinoma and testicular germ cell tumor sections (catalog applications; A05058-1 IHC image captions). A05058-1 is also listed for IF/ICC, with an IF image in HELA cells (catalog applications; A05058-1 IF image caption).
Which to pick: For tissue IHC, choose A05058-1: its own paraffin-section captions document EDTA retrieval at pH 8.0 and 2 μg/ml primary antibody; the fixative is unreported (A05058-1 IHC image captions). For IF/ICC, A05058-1 is the listed option, with a HELA-cell IF image at 5 μg/ml (catalog applications; A05058-1 IF image caption). For mouse or rat samples, A05058-1 lists reactivity with both species, while the supplied images show human samples; clone type is unreported (catalog reactivity; A05058-1 image captions; catalog clone field).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry O43303 (CP110_HUMAN, Centriolar coiled-coil protein of 110 kDa).
- Human Protein Atlas. CCP110 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. CCP110 subcellular location (ICC-IF): Localized to the centriolar satellites..
- Human Protein Atlas. CCP110 antibody validation summary (1 antibodies).
- lncRNA XIST/miR‑129‑2‑3p axis targets CCP110 to regulate the proliferation, invasion and migration of endometrial cancer cells. Experimental and therapeutic medicine 2023 — PMC9996364.
- Targeting USP7 Identifies a Metastasis-Competent State within Bone Marrow-Resident Melanoma CTCs. Cancer research 2018 — PMC6139068.
- CEP76 impairment at the centrosome-cilium interface contributes to a spectrum of ciliopathies. Science advances 2025 — PMC12533646.
- PubMed PMID:9455477 — UniProt-cited evidence.
- PubMed PMID:17974005 — UniProt-cited evidence.
- PubMed PMID:10493829 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for CCP110 (Centriolar coiled-coil protein of 110 kDa). Expected localisation Granular cytoplasm in tissue sections (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A05058-1). Validated IHC antibody: A05058-1 at 2-5μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Bronchus (Ciliated cells (cell body)); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet A05058-1); 2. Fixation: Image fixative and duration unreported (datasheet A05058-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A05058-1); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A05058-1); 8. Primary antibody: Rabbit anti-CCP110, 2-5μg/ml (datasheet A05058-1); 9. Primary incubation: Overnight at 4 °C (datasheet A05058-1). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Tissue staining has low agreement with RNA expression (HPA tissue IHC); Isoform / epitope: 2 isoforms; epitope coverage is unknown (UniProt); Regulation: Ubiquitination promotes degradation (UniProt). Evidence: UniProt O43303, HPA tissue IHC · Approved, HPA ICC-IF · centriolar satellites., Datasheet A05058-1, PMC9996364. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/CCP110/immunohistochemistry-ihc-guide.